Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Log out
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Article

Improved Neurodevelopmental Outcomes for Extremely Low Birth Weight Infants in 2000–2002

Deanne Wilson-Costello, Harriet Friedman, Nori Minich, Bonnie Siner, Gerry Taylor, Mark Schluchter and Maureen Hack
Pediatrics January 2007, 119 (1) 37-45; DOI: https://doi.org/10.1542/peds.2006-1416
Deanne Wilson-Costello
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harriet Friedman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nori Minich
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bonnie Siner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerry Taylor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Schluchter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maureen Hack
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Comments
Loading
Download PDF

Abstract

BACKGROUND. Neurodevelopmental impairment of extremely low birth weight infants increased in the 1990s. Modern therapeutic changes may have influenced more recent neonatal outcomes.

OBJECTIVE. We sought to compare neonatal therapies and outcomes among all extremely low birth weight infants born in 2000–2002 (period III) to 2 previous periods: 1982–1989 (period I) and 1990–1999 (period II).

METHODS. The population included 496 extremely low birth weight infants born at our perinatal center during period I, 749 during period II, and 233 during period III. Therapies, rates of death, and survival with and without impairment at 20 months' corrected age were compared.

RESULTS. Between periods I and II, survival increased from 49% to 68% as did neonatal morbidity. This resulted in increased survival without impairment but also increased survival with impairment. Changes in therapy during period III included an increase in antenatal steroid use and a decrease in postnatal steroid use, although the rate of chronic lung disease did not change. Sepsis decreased, as did severe intraventricular hemorrhage. On follow-up, the rate of cerebral palsy decreased from 13% to 5%, resulting in a decrease in neurodevelopmental impairment from 35% to 23%. As a result, during period III versus II, survival without impairment increased, whereas survival with impairment decreased.

CONCLUSION. Since 2000, neurodevelopmental impairment has decreased among extremely low birth weight infants. A variety of perinatal and neonatal factors were associated with the improved outcomes including increased antenatal steroid use and cesarean section delivery, as well as decreased sepsis, severe cranial ultrasound abnormalities, and postnatal steroid use despite no change in the rate of chronic lung disease.

  • extremely preterm infants
  • neurologic handicap
  • cerebral palsy

The evolution of neonatal intensive care therapy has resulted in dramatic improvements in the survival of extremely low birth weight (ELBW) infants (<1000 g).1 Although initial reports of declining mortality showed no increase in the rates of neurodevelopmental impairment,2,3 other studies suggested an increase in neurodevelopmental problems.4–6 Ethical concerns have been expressed that aggressive resuscitative efforts with tiny infants may result in increased rates of disability among survivors and substantial resource use.7,8 Additional reports suggest adverse effects of modern therapies such as postnatal steroid use.9 Although frequently used to treat chronic lung disease during the 1990s, the use of postnatal steroids has declined dramatically based on recommendations of The American Academy of Pediatrics.10 Quality improvement endeavors based on the sharing of best practice methods to decrease sepsis rates have also been implemented.11

Recently, we showed worsened neurodevelopmental outcomes for ELBW infants born in the 1990s, a period characterized by frequent postnatal steroid use and before the initiation of major efforts to decrease neonatal sepsis.12 In light of the recent changes in care practices, we sought to compare the rates of survival, neonatal morbidity, and neurodevelopmental impairment at 20 months' corrected age (CA) among ELBW children who were born at our perinatal center during 3 eras: 1982–1989, marked by enhanced assisted ventilation; 1990–1999, associated with the introduction of surfactant and antenatal and postnatal steroid therapy; and 2000–2002, marked by routine antenatal steroid therapy with decreased postnatal corticosteroid use and sepsis prevention initiatives.

METHODS

The study population included all 1478 live-born infants without major congenital malformations and with birth weights between 500 and 999 g who were delivered at our perinatal center, MacDonald Hospital for Women, during 3 periods (ie, 1982–1989 [period I; n = 496], 1990–1999 [period II; n = 749], and 2000–2002 [period III; n = 233]). The study periods were selected on a priori grounds on the basis of the following factors: the availability of uniform cranial ultrasound data for all patients born from 1982 onward, the initiation of antenatal steroid and surfactant therapies after 1990, and the implementation of quality improvement measures aimed at reducing postnatal corticosteroids and late-onset sepsis in 2000. Complete neurodevelopmental assessments to 20 months' CA were available for children born through 2002.

Our perinatal center is a tertiary referral center for high-risk pregnancies. Neonatal specialists attend all preterm deliveries. Decisions concerning active treatment of extremely preterm infants are made after consultation with the family, if possible, and/or according to the condition of the infant at birth. Despite some minor variations among individual neonatologists, there was general consensus during all 3 periods regarding the criteria for active resuscitation in the delivery room. Antenatal steroid therapy to enhance fetal pulmonary maturity was initiated after 1990.13 Neonatal care was rendered according to established guidelines, with no significant changes in the clinical facility or care team during the 3 periods.14,15 Maternal information included age, level of education, race and marital status, duration of gestation, antenatal steroid therapy, and mode of delivery. Gestational age was determined from the date of the last menstrual period and confirmed with obstetric measures, including ultrasonographic findings in the majority of cases. Infant birth data included birth weight, multiple birth status, Apgar scores, and use of assisted ventilation in the delivery room. Neonatal morbidity included respiratory distress, defined as need for oxygen therapy; chronic lung disease, defined as an oxygen dependence at 36 weeks' CA (CA-postmenstrual plus postnatal age)16; patent ductus arteriosus, confirmed with echocardiography; episodes of sepsis, defined as clinical signs of infection with a positive blood culture; necrotizing enterocolitis (NEC)17; intraventricular hemorrhage18; and periventricular leukomalacia. Routine cranial ultrasonographic evaluations were performed according to a similar schedule, with the initial evaluation between day of life 3 to 7 and subsequent evaluations on days of life 10, 30, 60, and before hospital discharge for all study subjects. Severe cerebral ultrasonographic abnormalities were categorized as the presence of either grade III or IV intraventricular hemorrhage, periventricular leukomalacia, or persistent of ventricular dilation at hospital discharge. Specific neonatal therapies included surfactant, duration of oxygen and ventilator therapy, indomethacin and postnatal steroids. Surfactant was used starting in 1990 for infants who required assisted ventilation and ≥30% ambient oxygen to maintain an arterial oxygen pressure of ≥50 mmHg. Postnatal steroid therapy was prescribed at the discretion of the attending neonatologist for infants with chronic lung disease and prolonged ventilator dependence. Indomethacin therapy was used to treat symptomatic patent ductus arteriosus.

Survival rates and neurodevelopmental status were measured to 18 to 20 months' CA. Measures of neurodevelopmental outcomes included neurosensory status and the Mental and Psychomotor Developmental Indices of the Bayley Scales of Infant Development (BSID).19 Children born after 1991 were tested with the revised BSID II, which has been shown to give lower scores than the original BSID used for children born 1982 through 1991. Thus, we devised a correction factor based on the published differences found in a sample of 200 children given both tests in counterbalanced order to compare the scores obtained with the BSID II with those obtained with the original BSID.20 For the Bayley mental development index (MDI), the correction factor ranged from 2 points for a score of 51 to 12 points for a score of 101. For the Bayley psychomotor development index (PDI), the correction factor ranged from 13 points for a score of 51 to 7 points for a score of 101. A neurologic examination of muscle tone was performed by either of 2 trained and certified examiners.21 Cerebral palsy was defined as a persistent but not unchanging disorder of movement and posture appearing in early life and attributable to a nonprogressive disorder of the brain, the result of interference during its development.22 Only patients with moderate-to-severe cerebral palsy were classified as having cerebral palsy for the study. Patients with isolated findings of increased or decreased tone in the extremities were classified as hypertonia or hypotonia on the basis of specific findings. Major neurologic impairments included cerebral palsy, hypotonia, hypertonia, and shunt-dependent hydrocephalus without other neurologic abnormality. Hypotonia and hypertonia were included in the category of major neurologic abnormality, because these conditions are considered by some to represent a variant of cerebral palsy. Shunt-dependent hydrocephalus without neurologic abnormality was also considered an impairment. Neurodevelopmental impairment included any major neurologic impairment, unilateral or bilateral blindness or deafness requiring a hearing aid, and/or an MDI of <70 on the BSID. Consistent criteria for defining neurodevelopmental impairment were used throughout the 21 years of study. Thirty-five neurologically impaired children (4 from period I, 22 from period II, and 9 from period III) were not testable with the BSID because of either behavioral problems or severe impairment. They were included among those with neurologic impairment but who do not have BSID scores reported. The 4 children from period I who had isolated blindness were inadvertently not included in our previous publication on the differences between survival and morbidity rates between the 1980s and 1990s; thus, rates of blindness and overall neurodevelopmental impairment shown for period I in this article were slightly greater than those previously reported.12 Parents provided informed consent for participation in the study, which was approved by the Institutional Review Board of University Hospitals of Cleveland.

ANALYSIS OF DATA

Trends in delivery room care, survival, neonatal morbidity, and outcomes at 20 months' CA were compared between the 3 periods of study. Statistical comparisons were made with unpaired t tests for continuous variables and χ2 analyses for categorical variables. We adjusted for gestational age via logistic regression in the examination of death and survival with and without impairment, because gestational age differed between periods (Table 1). In addition, analysis of variance was performed to compare the mean MDI scores and rates of subnormal MDI over the 3 periods, controlling for gestational age and maternal education.

View this table:
  • View inline
  • View popup
TABLE 1

Comparison Of Perinatal and Birth Data

RESULTS

Characteristics of the Infants, Delivery Care, and Survival Rates

Table 1 presents a comparison of perinatal and birth data between periods I, II, and III. Birth weight was similar, although gestational age decreased significantly over the 3 periods. One infant from period III, who was born with a heartbeat at 17 weeks' gestation but died in the delivery room, was included in the study population because he met the World Health Organization's definition of a live birth.23 Infant race, gender, and number of multiple births did not differ. Antenatal steroid therapy was not used in period I, whereas 41% and 78% of mothers received this therapy in periods II and III respectively (P < .01). Cesarean sections increased significantly over the 3 periods and reached nearly half of all ELBW births during period III (P < .01). During period I, 81% of infants received assisted ventilation compared with 89% during period II (P < .01). There was no additional increase in the rate of assisted ventilation during period III. Surfactant was administered to only 1% of infants during period I, whereas 62% and 82% of infants received surfactant during periods II and III, respectively (P < .01).

A total of 242 (49%) of 496 infants survived to 20 months' CA during period I, compared with 508 (68%) of 749 during period II (P < .001). There was no significant change in survival between periods II and III at which time 165 (71%) of 233 infants survived. Compared with periods II and III, survivors from period I were of significantly higher birth weight (826 g vs 800 and 801 g; P < .01) and gestational age (26.7 weeks vs 26.2 and 26.0 weeks; P < .001).

Cause of Death

The most common cause of death was respiratory distress syndrome, accounting for approximately one third of all infants who died during the 3 periods. (Table 2) Another one third of the infants were not offered assisted ventilation because they were not considered viable; therefore, the cause of death was defined as “immaturity.” NEC as the primary cause of death occurred significantly more often during period III (P < .01). The increased mortality from NEC is unexplained in light of the overall reduction in sepsis during period III. During period I, 67% of deaths occurred before age 48 hours versus 58% and 57% during periods II and III, respectively (P = .06).

View this table:
  • View inline
  • View popup
TABLE 2

Primary Cause and Age of Death

Neonatal Morbidity of the Survivors

Chronic lung disease increased significantly from period I to II (P < .01) but did not change between period II and III (P = .33) (Table 3). Postnatal corticosteroid therapy, which was rarely used before 1990, increased dramatically in period II then decreased by nearly half in period III. The rate of sepsis also increased from period I to II (P < .001) then decreased significantly in period III (P < .001). The rate of grades III and IV intraventricular hemorrhage decreased between period II and III (P = .004). Periventricular leukomalacia increased between periods I and II (P = .018), likely because of improved diagnostic techniques, but did not change between period II and III. The overall rate of severe cranial ultrasound abnormalities decreased during period III (P < .001).

View this table:
  • View inline
  • View popup
TABLE 3

Neonatal Morbidity Among Surviving Infants of 500- to 999-g Birth Weight

Neurodevelopmental Outcomes at 20 Months' CA

Complete information on neurodevelopmental status at 20 months' CA was available for 218 (90%) survivors born during period I and 467 and 152 survivors (both 92%) born during periods II and III, respectively. Children who were followed had similar birth weights and gestational ages compared with those lost to follow-up. The educational level of the mothers was higher during period II, with 83% (417 of 500 subjects) having completed high school versus 77% (181 of 236 subjects) and 76% (123 of 162 subjects) during periods I and III, respectively (P = .03). Maternal race (64%, 61%, and 57% black) and marital status (56%, 54%, and 59% unmarried) did not differ between periods.

The overall rate of neurologic abnormalities was highest during period II (Table 4). Cerebral palsy, which increased from 8% in period I to 13% in period II, decreased to 5% in period III (P = .008). Blindness decreased between periods I and II, likely because of improvements in laser therapy for severe retinopathy of prematurity, but did not change between periods II and III. Deafness, which doubled between period I and II, decreased during period III.

View this table:
  • View inline
  • View popup
TABLE 4

Neurodevelopmental Outcomes at 20 Months' CA

There were no significant differences in the mean MDI or in the rates of subnormal MDI scores (<70) during the 3 periods (Table 4). However, the mean PDI was significantly lower in period II, most likely attributable to the higher rate of cerebral palsy during this period. The overall rates of neurodevelopmental impairment, including neurosensory abnormalities and/or subnormal MDI scores, increased from period I to II (28% vs 35%; P = .017), then decreased significantly to 23% in period III (P = .01). For children without neurosensory abnormality, the mean MDI scores were 90.4, 88.5, and 88.5, respectively, and rates of subnormal MDI (<70) were 12%, 14%, and 15% for the 3 periods, respectively. These did not differ between periods. Analysis of variance, controlling for gestational age and maternal education revealed no significant differences in mean MDI or rates of subnormal MDI over the 3 periods for all ELBW children and for the neurosensory normal subgroup.

Figure 1 illustrates the outcomes of all live-born infants. From period I to II, mortality decreased, and survival both with and without neurodevelopmental impairment increased significantly. The overall rates of death and/or impairment decreased from 67% to 57% (P < .01). Mortality did not change between periods II and III, but intact survival increased, whereas neurodevelopmental impairment decreased. The overall rate of death and/or impairment further decreased to 47% (P < .01).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Comparison of death and survival with and without neurodevelopmental impairment at 20 months' CA for 500- to 999- g birth weight infants born during 3 periods: 1982–1989; 1990–1999, and 2000–2002. a Neurosensory abnormality and/or MDI <70.

In a comparison of periods I and II, after adjustment for gestational age, period II had a lower death rate, odds ratio (odds ratio [OR]: 0.4; 95% confidence interval [CI]: 0.3–0.6), a higher rate of survival with impairment (OR: 2.0; 95% CI: 1.5–2.8), and a higher rate of survival without impairment (OR: 1.5; 95% CI: 1.2–1.9). A similar comparison between periods II and III yields an OR for death of 0.9 (95% CI: 0.6–1.2); for survival with impairment, the OR was 0.6 (95% CI: 0.4–0.96); and for survival without impairment, the OR was 1.5 (95% CI: 1.1–2.0).

To determine the relative effect of birth period and various perinatal and neonatal factors contributing to increased survival without neurodevelopmental impairment, logistic regression analysis was performed for patients from study periods II and III who survived to age 7 days, controlling for birth weight, gender, study period, and significant factors in the univariate comparison including antenatal steroid use, mode of delivery, surfactant therapy, severe cranial ultrasound abnormality, sepsis, and postnatal steroid exposure. Patients who survived < 7 days were omitted from the analysis because they frequently lacked cranial ultrasound data and were often not eligible for postnatal steroid therapy. After adjusting for the significant factors, neurodevelopmental impairment-free survival did not differ between periods II and III (OR: 0.93; 95% CI: 0.59–1.46; P = .76). Detailed examination of these results suggested that the lower rates of impairment during period III seen in the unadjusted analyses might be explained by significant decreases in postnatal steroid therapy, severe cranial ultrasound abnormality, and sepsis. These 3 factors were all significant predictors of neurodevelopmental impairment-free survival in the multivariate logistic model. ORs and 95% CIs for impairment-free survival were 0.59 (0.41–0.85) for postnatal steroid therapy; 0.16 (0.11–0.25) for severe cranial ultrasound abnormalities and 0.64 (0.45–0.89) for sepsis, with P values of <.01, <.001, and 0.01, respectively. In contrast, a protective effect for antenatal steroids on intact survival bordered on significant (OR: 1.37; 95% CI: 0.96–2.0; P = .09). The same multivariate logistic model to predict neurodevelopmentally intact survival using significant antenatal and birth factors such as study period, birth weight, gender, cesarean section delivery, antenatal steroid treatment, and surfactant therapy was performed for the entire population of infants born during periods II and III. In this analysis, postnatal factors, such as severe cranial ultrasound abnormalities, sepsis, and postnatal steroid treatment were not included because of the lack of opportunity for exposure to these factors for infants who died before 7 days age. In this analysis, the protective effect of antenatal steroids on intact survival reached significance (OR: 2.01; 95% CI: 1.48–2.74; P < .001). Cesarean section delivery and female gender were also significantly protective (OR: 1.8; 95% CI: 1.35–2.46; P < 0001 and OR: 2.2; 95% CI: 1.62–2.94; P < .001, respectively). Surfactant did not have a protective effect on intact survival in either multivariate logistic analysis. Of interest, multivariate analysis using both prenatal and postnatal factors performed for infants surviving to follow-up suggests that although antenatal steroids, female gender, and cesarean section delivery enhanced survival, severe cranial ultrasound abnormalities, sepsis, and postnatal steroid therapy predicted neurodevelopmental outcome.

DISCUSSION

Our results indicate that although survival rates for ELBW infants born at our perinatal center increased during the 1990s compared with the 1980s, no additional increase in survival occurred during 2000–2002. During the 1990s, the perinatal approach to ELBW infants became more aggressive with increased use of antenatal steroids, cesarean section delivery, surfactant therapy, assisted ventilation, and postnatal steroids. The associated neonatal morbidities increased, resulting in higher rates of neurodevelopmental impairment. Between 2000 and 2002, antenatal steroid use continued to increase, but postnatal steroid use declined dramatically after reports of increased rates of cerebral palsy.24–28 Despite this decrease in postnatal steroid use, there was no change in the rate of chronic lung disease during period III. At the same time, rates of sepsis and severe intraventricular hemorrhage also decreased. Neurodevelopmental outcomes improved for ELBW infants born during 2000–2002, with decreased rates of cerebral palsy, deafness, and overall neurodevelopmental impairment. During the 1990s, there was increased survival both with and without impairment. Since the year 2000, there have been improved neurodevelopmental outcomes, with increased survival without impairment and a decrease in survival with neurodevelopmental impairment. A variety of perinatal and neonatal factors were responsible for the improved outcomes, including decreases in postnatal steroid therapy, severe cranial ultrasound abnormalities, and sepsis.

Increasing rates of neurodevelopmental disability among ELBW infants born in the early 1990s have been previously reported.12,29,30 However, others suggest stable or slightly improved neurodevelopmental outcomes associated with increased antenatal steroid use.31,32 Our study, which is the first, to our knowledge, to report improved outcomes for 2000–2002 in conjunction with decreased use of postnatal steroids, suggests that the adverse neurodevelopmental outcomes during the 1990s likely relate to postnatal corticosteroid use and sepsis. Dexamethasone, the glucocorticoid most commonly used in the clinical setting, has been shown to impair cortical growth among preterm infants.33–35 Research has demonstrated that the preferential binding of dexamethasone to the glucocorticoid receptors of the dentate gyrus induces apoptosis and neuronal cell death.36

Several authors have noted an association between sepsis and cerebral palsy.37–40 A recent report of ELBW infants identifies sepsis as an independent risk factor for neurodevelopmental impairment, including cerebral palsy and subnormal cognition.41 Inflammatory cytokines, released during intrauterine infection, are considered to be catalysts for the development of periventricular leukomalacia and subsequent cerebral palsy.42,43 Recent neonatal quality improvement initiatives have introduced practice guidelines to minimize the risk of nosocomial sepsis.44 Our neonatal unit now emphasizes aseptic precautions for all central line sites, use of in-line blood sampling equipment, and meticulous hand-washing. Such policies together with restriction of postnatal steroid therapy, which is associated with increased susceptibility to infections, may have contributed to our improved neurodevelopmental outcomes.45,46

The strengths of our study include the relatively large inborn population and the high follow-up rates. The major limitation concerns the relatively short-term nature of the follow-up. Children diagnosed with cerebral palsy may “outgrow” the diagnosis in later years,47 and cognitive scores may improve later in childhood.48,49 The recent 3-year observational study period may not provide sufficient time to fully reveal the impact of therapeutic interventions on outcome. The presentation of outcomes by birth weight rather than gestational age will include small-for-gestational-age infants who are likely more mature. This study represents a predominantly urban population. Thus, its findings may not be generalizable to other neonatal centers with larger numbers of suburban infants.

Survival did not increase between periods II and III, as has also been shown by others.1,50 Because additional reduction in the mortality rates of ELBW infants seems unlikely, future efforts must concentrate on reducing neonatal morbidity. Although the decrease in cerebral palsy since 2000 is encouraging, the lack of improvement in MDI is unexplained and necessitates additional research for interventions that may enhance cognitive function. Sociodemographic and environmental factors may contribute to differences in cognitive outcomes. Although maternal education was significantly higher during period II, analysis of variance controlling for maternal education did not change our outcomes. Whereas some studies on the effects of early educational intervention programs have demonstrated improved outcomes for children born to mothers of low sociodemographic status,51,48 other reports have failed to demonstrate a sustained benefit.52,53 The use of inhaled nitric oxide as rescue therapy to reduce death or chronic lung disease among preterm infants with respiratory failure has also been shown to decrease the rates of intraventricular bleeds and improve cognitive outcomes.54,55 However, these findings have been tempered by studies that suggest either no improvement or worsened outcomes among ELBW infants.56,57 Meanwhile, the iatrogenic detrimental effects of postnatal steroids caution against the premature use of new therapies for the most vulnerable infants before a thorough evaluation by randomized, controlled clinical trials.58

CONCLUSIONS

Advances in perinatal care before 2000 resulted in improved survival but with either an increase or lack of reduction in neurodevelopmental impairment.2,12 Greater numbers of disabled survivors result not only in enormous family impact but also the need for additional resources for support in school, the home, and workplace. The decreased morbidity and impairment that we have described since 2000 is a step in the right direction. However, as resuscitation and neonatal care continue to save the lives of the smallest and least mature infants, additional advances will be required to increase survival free of neonatal morbidity and neurodevelopmental impairment. Longer term follow-up of this population will be essential to evaluate the effects on quality of life for infants and their families and to help determine what constitutes appropriate care without doing harm. At the present time, prematurity cannot be prevented.59 Emphasis on decreasing the number of multiple births resulting from infertility therapies accompanied by minimizing iatrogenesis and morbidity associated with sepsis and postnatal steroid therapy may hold promise for improved long-term outcomes.

Acknowledgments

This work was supported by grant M01RR00080, General Clinical Research Center, and partially supported by grant HD21364 from the National Institute of Child Health and Human Development Neonatal Research Network.

We thank Angelia Williams and Nancy Newman, RN, for help in conducting this research.

Footnotes

    • Accepted September 25, 2006.
  • Address correspondence to Deanne Wilson-Costello, MD, Division of Neonatology, Rainbow Babies & Children's Hospital, University Hospitals of Cleveland, 11100 Euclid Ave, Cleveland, OH 44106-6010. E-mail: drfjcmd{at}aol.com
  • The authors have indicated they have no financial relationships relevant to this article to disclose.

ELBW—extremely low birth weight • CA—corrected age • BSID—Bayley Scales of Infant Development • MDI—mental developmental index • PDI—psychomotor developmental index • NEC—necrotizing enterocolitis • OR—odds ratio • CI—confidence interval

REFERENCES

  1. ↵
    Fanaroff AA, Hack M, Walsh MC. The NICHD Neonatal Research Network: changes in practice and outcomes during the first 15 years. Semin Perinatol.2003;27 :281– 287
    OpenUrlCrossRefPubMed
  2. ↵
    Doyle LW, for The Victorian Infant Collaborative Study Group. Improved outcome into the 1990s for infants weighing 500–999 g at birth. Arch Dis Child Fetal Neonatal Ed.1997;77 :F91– F94
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Robertson C, Hrynchyshyn GJ, Etches PC, Pain KS. Population-based study of the incidence, complexity and severity of neurologic disability among survivors weighing 500 through 1250 grams at birth: a comparison of two birth cohorts. Pediatrics.1992;90 :750– 755
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Lorenz JM, Wookiever DE, Jetton JR, Paneth N. A quantitative review of mortality and developmental disability in extremely premature newborns. Arch Pediatr Adolesc Med.1998;152 :425– 435
    OpenUrlCrossRefPubMed
  5. Emsley HCA, Wardle SP, Sims DG, Chiswick ML, D'Souza SWD. Increased survival and deteriorating developmental outcome in 23–25 week old gestation infants, 1990–1994 compared with 1984–1989. Arch Dis Child Fetal Neonatal Ed.1998;78 :F99– F104
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Hack M, Friedman H, Fanaroff AA. Outcome of extremely low birth weight infants. Pediatrics.1996;98 :931– 937
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Hack M, Taylor HG, Drotar D, et al. Chronic conditions, functional limitations, and special health care needs of school-age children born extremely low birth weight in the 1990s. JAMA.2005;294 :1– 9
    OpenUrl
  8. ↵
    Marlow N, Wolke D, Bracewell MA, Samara M, for the EPICure Study Group. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med.2005;352 :9– 19
    OpenUrlCrossRefPubMed
  9. ↵
    Stark AE, Carlo WA, Tyson JE, et al. Adverse effects of early dexamethasone in extremely low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med.2001;344 :95– 101
    OpenUrlCrossRefPubMed
  10. ↵
    American Academy of Pediatrics, Committee on Fetus and Newborn; Canadian Paediatric Society, Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics.2002;109 :330– 338
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Kilbride HW, Wirtschafter DD, Powers RJ, Sheehan MD. Implementation of evidence-based potentially better practices to decrease nosocomial infections. Pediatrics.2003;111(4) . Available at: www.pediatrics.org/cgi/content/full/111/4/SE1/e519
  12. ↵
    Wilson-Costello D, Friedman H, Minich N, Fanaroff A, Hack M. Improved survival rates with increased neurodevelopmental disability for extremely low birth weight infants in the 1990s. Pediatrics.2005;115 :997– 1003
    OpenUrlAbstract/FREE Full Text
  13. ↵
    National Institutes of Health. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Statement.1994;12 :1– 24
    OpenUrlPubMed
  14. ↵
    Fanaroff AA, Martin RJ, eds. Neonatal-Perinatal Medicine. 7th ed. Philadelphia, PA: WB Saunders; 2001
  15. ↵
    American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Guidelines for Perinatal Care. 5th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2002
  16. ↵
    Shennan AT, Dunn MJ, Ohlsson A, Lenox K. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics.1988;82 :527– 532
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis: therapeutic decisions based on clinical staging. Ann Surg.1978;187 :1– 7
    OpenUrlCrossRefPubMed
  18. ↵
    Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhages; a study of infants with birthweights less than 1500 grams. J Pediatr.1978;92 :529– 534
    OpenUrlCrossRefPubMed
  19. ↵
    Bayley N. Bayley Scales of Infant Development. New York, NY: Psychological Corp; 1969
  20. ↵
    Bayley N. Bayley Scales of Infant Development. 2nd ed. San Antonio, TX: Psychological Corp; 1993
  21. ↵
    Amiel-Tison C, Stewart AL. Follow-up studies in the first five years of life: a pervasive assessment of neurologic function. Arch Dis Child.1989;64 :496– 502
    OpenUrlFREE Full Text
  22. ↵
    Bax M. Terminology and classification of cerebral palsy. Dev Med Child Neurol.1964;6 :295– 297
    OpenUrlPubMed
  23. ↵
    World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th rev. Geneva, Switzerland: World Health Organization; 1992
  24. ↵
    Kramer MS, Platt RW, Wen SW, et al. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics.2001;108(2) . Available at: www.pediatrics.org/cgi/content/full/108/2/e35
  25. Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med.2004;350 :1304– 1313
    OpenUrlCrossRefPubMed
  26. Baud O. Postnatal steroid treatment and brain development. Arch Dis Child.2004;89 :96– 100
    OpenUrlFREE Full Text
  27. Short EJ, Klein NK, Lewis BA, et al. Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics.2003;112(5) . Available at: www.pediatrics.org/cgi/content/full/112/5/e359
  28. ↵
    Barrington KJ. The adverse neurodevelopmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr.2001;1 :1
    OpenUrlPubMed
  29. ↵
    Vohr BR, Wright LL, Dusick AM, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993–1994. Pediatrics.2000;105 :1216– 1226
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Hintz SR, Kendrick DE, Vohr BR, et al. Changes in neurodevelopmental outcomes at 18 to 22 months' corrected age among infants of less than 25 weeks' gestational age born in 1993–1999. Pediatrics.2005;115 :1645– 1651
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Vohr BR, Wright LL, Poole K, et al. Neurodevelopmental outcomes of extremely low birth weight infants less than 32 weeks' gestation between 1993 and 1998. Pediatrics.2005;116 :635– 643
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Doyle LW, Anderson PJ; Victorian Infant Collaborative Study Group. Improved neurosensory outcome at 8 years of age of extremely low birth weight children born in Victoria over 3 different eras. Arch Dis Child Fetal Neonatal Ed.2005;90 :F484– F485
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Nosarti C, Al-Asady MHS, Frangou S, Stewart AL, Rifkin L, Marray RM. Adolescents who were born very preterm have decreased brain volumes. Brain.2002;125 :1616– 1623
    OpenUrlAbstract/FREE Full Text
  34. Abernethy LJ, Cooke RW, Foulder-Hughes L. Caudate and hippocampal volumes, intelligence, and motor impairment in 7-year-old children who were born preterm. Pediatr Res.2004;55 :884– 893
    OpenUrlCrossRefPubMed
  35. ↵
    Lodygensky GA, Rademaker K, Zimine S, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics.2005;116 :1– 7
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Hassan AH, von Rosenstiel P, Patchev VK, Holsboer F, Almeida OF. Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone. Exp Neurol.1996;140 :43– 52
    OpenUrlCrossRefPubMed
  37. ↵
    Wu YW, Colford JM. Chorioamnionitis as a risk factor for cerebral palsy: a meta-analysis. JAMA.2000;284 :1417– 1424
    OpenUrlCrossRefPubMed
  38. Wilson-Costello D, Borawski E, Friedman H, Redline R, Fanaroff A, Hack M. Perinatal correlates of cerebral palsy and other neurologic impairment among very low birth weight children. Pediatrics.1998;102 :315– 322
    OpenUrlAbstract/FREE Full Text
  39. Grether, JK, Nelson KB, Emery ES, III, Cummins SK. Prenatal and perinatal factors and cerebral palsy in very low birth weight infants. J Pediatr.1996;128 :407– 414
    OpenUrlCrossRefPubMed
  40. ↵
    Murphy DJ, Sellers S, MacKenzie IZ, Yudkin PL, Johnson AM. Case control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet.1995;346 :1449– 1454
    OpenUrlCrossRefPubMed
  41. ↵
    Stoll BJ, Hansen NI, Adams-Chapman I, et al. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA.2004;292 :2357– 2365
    OpenUrlCrossRefPubMed
  42. ↵
    Dammann O, Leviton A. Maternal intrauterine infection, cytokines and brain damage in the preterm newborn. Pediatr Res.1997;42 :1– 8
    OpenUrlCrossRefPubMed
  43. ↵
    Yoon BH, Jun JK, Romero R, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1B, and tumor necrosis factor-a), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol.1997;177 :19– 26
    OpenUrlCrossRefPubMed
  44. ↵
    Aly H, Herson V, Duncan A, et al. Is bloodstream infection preventable among premature infants? A tale of two cities. Pediatrics.2005;115 :1513– 1518
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Kumar P. Effect of decreased use of postnatal corticosteroids on morbidity in extremely low birthweight infants. Am J Perinatol.2005;22 :77– 81
    OpenUrlCrossRefPubMed
  46. ↵
    Kaempf JW, Campbell B, Sklar RS, et al. Implementing potentially better practices to improve neonatal outcomes after reducing postnatal dexamethasone use in infants born between 501 and 1250 grams. Pediatrics.2003;111(4 pt 2) . Available at: www.pediatrics.org/cgi/content/full/111/4/SE1/e534
  47. ↵
    Nelson KB, Ellenberg JH. Children who “outgrew” cerebral palsy. Pediatrics.1982;69 :529– 536
    OpenUrlAbstract/FREE Full Text
  48. ↵
    Ment LR, Vohr B, Allen W, et al. Change in cognitive function over time in very low-birth-weight infants. JAMA.2003;289 :705– 711
    OpenUrlCrossRefPubMed
  49. ↵
    Hack M, Taylor HG, Drotar D, et al. Poor predictive validity of the Bayley Scales of Infant Development for cognitive function of extremely low birth-weight children at school age. Pediatrics.2005;116 :333– 341
    OpenUrlAbstract/FREE Full Text
  50. ↵
    Horbar JD, Badger GJ, Carpenter JH, et al. Trends in mortality and morbidity for very low birth weight infants, 1991–1999. Pediatrics.2002;110 :143– 151
    OpenUrlAbstract/FREE Full Text
  51. ↵
    Berlin LJ, Brooks-Gunn J, McCarton C, McCormick MC. The effectiveness of early intervention: existing risk factors and pathways to enhanced development. Prev Med.1998;27 :238– 245
    OpenUrlCrossRefPubMed
  52. ↵
    Blauw-Hosper CH, Hadders-Algram. A systematic review of the effects of early intervention on motor development. Dev Med Child Neurol.2005;47 :421– 432
    OpenUrlCrossRefPubMed
  53. ↵
    Johnson S, Ring W, Anderson P, Marlow N. Randomized trial of parental support for families with very preterm children: outcome at 5 years. Arch Dis Child.2005;90 :909– 915
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med.2003;349 :2099– 2107
    OpenUrlCrossRefPubMed
  55. ↵
    Mestan KKL, Marks JD, Hecox K, Huo D, Schreiber MD. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med.2005;353 :23– 32
    OpenUrlCrossRefPubMed
  56. ↵
    Field D, Elbourne D, Truesdale A, et al. Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: the INNOVO multicentre randomised controlled trial. Pediatrics.2005;115 :926– 936
    OpenUrlAbstract/FREE Full Text
  57. ↵
    Van Meurs KP, Wright LL, Ehrenkranz RA, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med.2005;353 :13– 22
    OpenUrlCrossRefPubMed
  58. ↵
    Silverman WA. Personal reflections on lessons learned from randomized trials involving newborn infants from 1951 to 1967. Clin Trials.2004;1 :179– 184
    OpenUrlFREE Full Text
  59. ↵
    Goldenberg RL, Jobe AH. Prospects for research in reproductive health and birth outcomes. JAMA.2001;285 :633– 639
    OpenUrlCrossRefPubMed
  • Copyright © 2007 by the American Academy of Pediatrics
PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Pediatrics
Vol. 119, Issue 1
January 2007
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Improved Neurodevelopmental Outcomes for Extremely Low Birth Weight Infants in 2000–2002
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Improved Neurodevelopmental Outcomes for Extremely Low Birth Weight Infants in 2000–2002
Deanne Wilson-Costello, Harriet Friedman, Nori Minich, Bonnie Siner, Gerry Taylor, Mark Schluchter, Maureen Hack
Pediatrics Jan 2007, 119 (1) 37-45; DOI: 10.1542/peds.2006-1416

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Improved Neurodevelopmental Outcomes for Extremely Low Birth Weight Infants in 2000–2002
Deanne Wilson-Costello, Harriet Friedman, Nori Minich, Bonnie Siner, Gerry Taylor, Mark Schluchter, Maureen Hack
Pediatrics Jan 2007, 119 (1) 37-45; DOI: 10.1542/peds.2006-1416
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Abstract
    • METHODS
    • ANALYSIS OF DATA
    • RESULTS
    • DISCUSSION
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • Comments

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Improving incidence trends of severe intraventricular haemorrhages in preterm infants <32 weeks gestation: a cohort study
  • Assessing whether early attention of very preterm infants can be improved by an omega-3 long-chain polyunsaturated fatty acid intervention: a follow-up of a randomised controlled trial
  • Neurodevelopmental Impairment Among Extremely Preterm Infants in the Neonatal Research Network
  • Changes in survival and neurodevelopmental outcomes of infants born at <25 weeks gestation: a retrospective observational study in tertiary centres in Japan
  • Developmental Assessments in Preterm Children: A Meta-analysis
  • Cerebral Palsy, Developmental Coordination Disorder, Visual and Hearing Impairments in Infants Born Preterm
  • Brain damage of the preterm infant: new insights into the role of inflammation
  • Obstetric and Neonatal Care Practices for Infants 501 to 1500 g From 2000 to 2009
  • Outcomes of Infants Born at 22 and 23 Weeks' Gestation
  • Neonatal Nurses and Therapists Perceptions of Positioning for Preterm Infants in the Neonatal Intensive Care Unit
  • Postnatal corticosteroids and neurodevelopmental outcomes in extremely low birthweight or extremely preterm infants: 15-year experience in Victoria, Australia
  • Babies born at the threshold of viability: changes in survival and workload over 20 years
  • Postnatal intravenous steroids and long-term neurological outcome: recommendations from meta-analyses
  • Qualitative Brain MRI at Term and Cognitive Outcomes at 9 Years After Very Preterm Birth
  • Parental Psychological Well-Being and Behavioral Outcome of Very Low Birth Weight Infants at 3 Years
  • Stability of Cognitive Outcome From 2 to 5 Years of Age in Very Low Birth Weight Children
  • Incidence and Timing of Presentation of Necrotizing Enterocolitis in Preterm Infants
  • Changing long-term outcomes for infants 500-999 g birth weight in Victoria, 1979-2005
  • Interpreting data on the health outcomes of extremely preterm babies
  • Neonatal intensive care outcomes and resource utilisation of infants born <26 weeks in the former Trent region: 2001-2003 compared with 1991-1993
  • Two-year outcomes from very low birthweight infants in a geographically defined population across 10 years, 1993-2002: comparing 1993-1997 with 1998-2002
  • Two-year neurodevelopmental outcome of preterm born children <=750 g at birth
  • Impact at Age 11 Years of Major Neonatal Morbidities in Children Born Extremely Preterm
  • Prediction of Neurodevelopmental and Sensory Outcome at 5 Years in Norwegian Children Born Extremely Preterm
  • Neonatal outcomes of preterm infants in breech presentation according to mode of birth in Canadian NICUs
  • Cerebral palsy rates by birth weight, gestation and severity in North of England, 1991-2000 singleton births
  • Does bronchopulmonary dysplasia contribute to the occurrence of cerebral palsy among infants born before 28 weeks of gestation?
  • Early-Childhood Neurodevelopmental Outcomes Are Not Improving for Infants Born at <25 Weeks' Gestational Age
  • Regulation of treatment of infants at the edge of viability in Italy: the role of the medical profession?
  • Outcomes of children born very preterm in Europe
  • Special Health Care Needs of Infants Born at the Limits of Viability
  • Changes in care and outcome of very preterm babies in the Parisian region between 1998 and 2003
  • Predicting Time to Hospital Discharge for Extremely Preterm Infants
  • Outcome of Extreme Prematurity: A Prospective Comparison of 2 Regional Cohorts Born 20 Years Apart
  • Morbidities and Hospital Resource Use During the First 3 Years of Life Among Very Preterm Infants
  • Counseling Pregnant Women Who May Deliver Extremely Premature Infants: Medical Care Guidelines, Family Choices, and Neonatal Outcomes
  • Permanent Bilateral Sensory and Neural Hearing Loss of Children After Neonatal Intensive Care Because of Extreme Prematurity: A Thirty-Year Study
  • First-Week Protein and Energy Intakes Are Associated With 18-Month Developmental Outcomes in Extremely Low Birth Weight Infants
  • Psychological stress of parents of preterm infants enrolled in an early discharge programme from the neonatal intensive care unit: a prospective randomised trial
  • A Pilot Randomized, Controlled Trial of Later Treatment With a Peptide-Containing, Synthetic Surfactant for the Prevention of Bronchopulmonary Dysplasia
  • A Novel Quantitative Simple Brain Metric Using MR Imaging for Preterm Infants
  • Finding the Optimal Postnatal Dexamethasone Regimen for Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Systematic Review of Placebo-Controlled Trials
  • Extremely preterm births: recommendations for treatment in European countries
  • Using Intensive Care Technology in the Delivery Room: A New Concept for the Resuscitation of Extremely Preterm Neonates
  • Improving head growth in preterm infants - a randomised controlled trial II: MRI and developmental outcomes in the first year
  • Improving head growth in very preterm infants - a randomised controlled trial I: neonatal outcomes
  • Impact of Cesarean Section on Neonatal Mortality Rates Among Very Preterm Infants in the United States, 2000-2003
  • NMDA Receptor Blockade with Memantine Attenuates White Matter Injury in a Rat Model of Periventricular Leukomalacia
  • Pathogenesis of cerebral white matter injury of prematurity
  • Outcomes of Extremely Low Birth Weight (<1 kg) and Extremely Low Gestational Age (<28 Weeks) Infants With Bronchopulmonary Dysplasia: Effects of Practice Changes in 2000 to 2003
  • Improved Outcomes of Extremely Low Birth Weight Infants
  • Google Scholar

More in this TOC Section

  • Relational, Emotional, and Pragmatic Attributes of Ethics Consultations at a Children’s Hospital
  • Verbal Autopsies for Out-of-Hospital Infant Deaths in Zambia
  • Uncertainty at the Limits of Viability: A Qualitative Study of Antenatal Consultations
Show more Articles

Similar Articles

Subjects

  • Neurology
    • Neurology
  • Fetus/Newborn Infant
    • Fetus/Newborn Infant
  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Open Access
  • Reviewer Guidelines
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2021 American Academy of Pediatrics